Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 15/20 | 0.40 |
| ▸ | TP53 | P04637 | 6/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 3/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23993481 | 1.00 | MDM2 (0.40) | MDM2TP53PDE10AHSD11B1MDM4 | |
| SCHEMBL23993476 | 1.00 | MDM2 (0.40) | MDM2TP53PDE10AHSD11B1MDM4 | |
| SCHEMBL25005349 | 0.88 | MTOR (0.33) | MDM2TP53PDE10AMTOR | |
| SCHEMBL30224159 | 0.88 | MDM2 (0.36) | MDM2TP53PDE10AMDM4MTOR | |
| SCHEMBL23994952 | 0.88 | MDM2 (0.36) | MDM2TP53PDE10AMDM4MTOR | |
| SCHEMBL23993986 | 0.87 | SYK (0.37) | MDM2PDE10AMTOR | |
| SCHEMBL30224492 | 0.87 | SYK (0.37) | MDM2PDE10AMTOR | |
| SCHEMBL23994182 | 0.87 | SYK (0.37) | MDM2PDE10AMTOR | |
| SCHEMBL23994948 | 0.87 | CYP1A2 (0.37) | MDM2PDE10AMTOR | |
| SCHEMBL23994947 | 0.87 | CYP1A2 (0.37) | MDM2PDE10AMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | MDM2 2083/4885TP53 85/4885PDE10A 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.